LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.
溫馨提示:LY2784544 (Gandotinib),品質穩(wěn)定,純度>98+%,僅供實驗使用.產(chǎn)品質量嚴格控制,保證品質。
南京百鑫德諾生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!